The first presentation, by Dr Sairabanu Sobwalia, focused on the intricate interplay between lipid disorders and endocrine dysfunction, a captivating yet challenging realm known as lipocrinology. "Often overlooked, this nexus holds pivotal significance in clinical practice, shaping the understanding of disease pathogenesis and treatment paradigms," Dr Sobwalia said.
The presentation began with the case of a 36-year-old Asian female, presenting with a complex medical history including polycystic ovary syndrome and primary hypothyroidism. "This case serves as a poignant example of the conundrum clinicians encounter when traditional risk profiles fall short in capturing the full spectrum of cardiovascular risk associated with atypical lipid presentations," Dr Sobwalia said.
Dyslipidaemia focus
Extensive studies underscore the alarming ubiquity of dyslipidaemia, highlighted in Dr Sobwalia's presentation. In regions like Africa, where the epidemiological landscape is in flux, heightened vigilance is warranted as non-communicable diseases compound traditional health challenges.
"Endocrine disorders play a pivotal role in shaping lipid profiles," Dr Sobwalia said. Conditions such as hypothyroidism, hyperprolactinemia, and Cushing's syndrome wield diverse effects on lipid metabolism, necessitating tailored interventions to address their multifaceted implications. A nuanced comprehension of these associations not only informs risk assessment but also guides the formulation of therapeutic strategies aimed at optimising patient outcomes.
Furthermore, the realm of pharmacotherapy in endocrine disorders introduces additional layers of complexity. While certain pharmacological agents confer lipid-lowering benefits, others may inadvertently exacerbate dyslipidemia, underscoring the imperative of a personalized treatment approach. Considerations surrounding hormone replacement therapy in postmenopausal women, for instance, demand meticulous evaluation owing to its variable impact on lipid profiles and cardiovascular health.
In navigating the management of dyslipidaemia within the context of endocrine disorders, the importance of screening for underlying endocrine pathology cannot be overstated. However, it is crucial to exercise clinical judgment, recognising that indiscriminate testing may not yield actionable insights in every case.
"Lipocrinology elucidates the dynamic interplay between lipids and endocrine function, fostering improved patient outcomes and enhanced quality of care," Dr Sobwalia said.
Discussion session
In discussions following the presentation, several valuable insights emerged. Speakers emphasised the importance of evaluating both lipid and endocrine disorders at the same time, recognising their high coexistence and their implications for cardiovascular risk.
The speakers emphasised the importance of risk stratification and patient education in statin therapy. They highlighted the array of therapeutic options available and the need for personalised approaches to achieve LDL targets. In their closing remarks, the panelists reiterated the interconnected nature of lipid and endocrine disorders, advocating for a holistic approach to patient care.
